Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 57Carcinoma, Hepatocellular 45Colorectal Neoplasms 18Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Esophageal Neoplasms 9Advanced Gastric Cancer 9Biliary Tract Neoplasms 8Pancreatic Neoplasms 6Liver Neoplasms 5Neoplasms 3Neoplasm Metastasis 3Gastrointestinal Neoplasms 3Gastric Adenocarcinoma 3Digestive System Neoplasms 3Recurrence 2Metastatic Gastric Adenocarcinoma 2Locally Advanced Gastric Cancer 2Gastrointestinal Stromal Tumors 2Advanced Esophagus Cancer 2Uterine Cervical Neoplasms 1Stomach Diseases 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Peritoneal Metastases From Gastric Cancer 1Ovarian Neoplasms 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Intestinal Neoplasms 1Immunotherapy Gastrict Cancer 1Immunotherapy 1Hepatic Metastasis of Colorectal Cancer 1

Interventions

camrelizumab 1apatinib 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Primary Liver Cancer × apatinib × Gastrointestinal × Clear all
NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
157 enrolled 17 charts
Gastrointestinal

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡